RxDoctor Payments Data

Gregory Ortega, MD

Hematology & Oncology · Orange City, FLNPI 1720037989

Payments from drug & device makers

$17,759in general payments, 2019–2025

Across 21 payments — averaging $845.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tosoh Bioscience, Inc.$11K
  • Apellis Pharmaceuticals, Inc.$4K
  • Bristol Myers Squibb$3K
  • Seagen Inc.$187
  • Takeda Pharmaceuticals U.S.A., Inc.$99
  • Johnson & Johnson$85
  • plus $217 from 7 others

What the payments were for

  • Food & beverage$3893%
  • Education$1982%
  • Gifts$10,81295%

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,759 in reported general payments places this provider in the 50th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$2,334,065
Medicare patients
387
Services billed
154,575

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PromactaEltrombopag Olamine12$474,478
ReblozylLuspatercept-Aamt23$432,600
BrukinsaZanubrutinib24$342,721
PomalystPomalidomide11$248,131
Darzalex FasproDaratumumab-Hyaluronidase-Fihj22$227,618
ErleadaApalutamide13$224,182
ImfinziDurvalumab19$216,950
VerzenioAbemaciclib11$165,383
KeytrudaPembrolizumab12$136,072
PerjetaPertuzumab17$111,523
Everolimus12$108,421
TrazimeraTrastuzumab-Qyyp23$105,548
ProcritEpoetin Alfa46$103,543
EliquisApixaban100$83,858
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5011$74,970

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Reblozyl, Pomalyst$54$680,73134 claims
Johnson & JohnsonErleada, Procrit, Xarelto$85$352,63981 claims
AstraZenecaImfinzi$23$216,95019 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$99$74,97011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in Orange City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →